Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Metacrine

Metacrine?uq=3Oe4kK1Z
2014 FOUNDED
PRIVATE STATUS
21-30 EMPLOYEES
Series C LATEST DEAL TYPE
$65M LATEST DEAL AMOUNT
14 INVESTORS
Description

Develop of therapeutics that materially benefit patients with liver, GI and metabolic diseases. The company's are based on a novel non-bile acid chemical scaffold and a nuclear hormone receptor that has been clinically validated as a key drug target in hepatobiliary diseases such as primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) enabling patients to avail two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Primary Office
  • 3985 Sorrento Valley Boulevard
  • Suite C
  • San Diego, CA 92121
  • United States

+1 (858) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Metacrine’s full profile, request a free trial.

Metacrine Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series C) 06-Jun-2018 $65M 00000 00000 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series B) 07-Dec-2017 0000 000.00 0000 Completed Startup
1. Early Stage VC (Series A) 02-Nov-2016 $37.8M $37.8M 0000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Metacrine Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A 36,099,978 $0.000100 6% $1 $1 1x $1 35.6%
To view this company’s complete Cap Table, request access »

Metacrine Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
ArrowMark Partners Asset Manager Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
Franklin Templeton Investments Asset Manager Minority 000 0000 000000 0
Invus Group PE/Buyout Minority 000 0000 000000 0
Lilly Asia Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Metacrine Executive Team (9)

Name Title Board
Seat
Contact
Info
Ken Song MD President, Chief Executive Officer & Board Director
Trisha Millican Chief Financial Officer
Nicholas Smith Ph.D Senior Vice President, Chemistry
Karl Cremer Vice President, Clinical Operations
Eric Bischoff Vice President, Development and Business Operations

2 Former Executives

You’re viewing 5 of 9 executives. Get the full list »

Metacrine Board Members (7)

Name Representing Role Since Contact
Info
Amir Nashat Ph.D Polaris Partners Board Member 000 0000
Carol Gallagher New Enterprise Associates Board Member 000 0000
Ken Song MD Metacrine President, Chief Executive Officer & Board Director 000 0000
Kristina Burow ARCH Venture Partners Board Member 000 0000
Richard Heyman Ph.D Self Executive Chairman & Co-Founder 000 0000
You’re viewing 5 of 7 board members. Get the full list »